Cyclin‐dependent kinase 5 (<scp>CDK5</scp>) inhibitors in Parkinson disease-Reference-Cited by-同舟云学术

Cyclin‐dependent kinase 5 (CDK5) inhibitors in Parkinson disease

Published:2024-06 Issue:11 Volume:28 Page:
ISSN:1582-1838
Container-title:Journal of Cellular and Molecular Medicine
language:en
Short-container-title:J Cellular Molecular Medi

Author:

Alrouji Mohammed¹,Al‐kuraishy Haydar M.²,Al‐Gareeb Ali I.²,Alshammari Mohammed S.¹,Alexiou Athanasios³⁴⁵⁶^ORCID,Papadakis Marios⁷,Bahaa Mostafa M.⁸^ORCID,Batiha Gaber El‐Saber⁹

Affiliation:

1. Department of Clinical Laboratory Sciences, College of Applied Medical Sciences Shaqra University Shaqra Saudi Arabia

2. Department of Clinical Pharmacology and Medicine, College of Medicine Mustansiriyah University Baghdad Iraq

3. University Centre for Research & Development, Chandigarh University Mohali Punjab India

4. Department of Science and Engineering Novel Global Community Educational Foundation Hebersham New South Wales Australia

5. Department of Research & Development, Funogen Athens Greece

6. Department of Research & Development, AFNP Med Wien Austria

7. Department of Surgery II University Hospital Witten‐Herdecke Wuppertal Germany

8. Pharmacy Practice Department, Faculty of Pharmacy Horus University New Damietta Egypt

9. Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine Damanhour University Damanhour Egypt

Abstract

AbstractCyclin‐dependent kinase 5 (Cdk5) is a protein expressed in postmitotic neurons in the central nervous system (CNS). Cdk5 is activated by p35 and p39 which are neuron regulatory subunits. Cdk5/p35 complex is activated by calpain protease to form Cdk5/p35 which has a neuroprotective effect by regulating the synaptic plasticity and memory functions. However, exaggerated Cdk5 is implicated in different types of neurodegenerative diseases including Parkinson disease (PD). Therefore, modulation of Cdk5 signalling may mitigate PD neuropathology. Therefore, the aim of the present review was to discuss the critical role of Cdk5 in the pathogenesis of PD, and how Cdk5 inhibitors are effectual in the management of PD. In conclusion, overactivated Cdk5 is involved the development of neurodegeneration, and Cdk5/calpain inhibitors such as statins, metformin, fenofibrates and rosiglitazone can attenuate the progression of PD neuropathology.

Funder

Universität Witten/Herdecke

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jcmm.18412

Reference92 articles.

1. A review on cyclin-dependent kinase 5: An emerging drug target for neurodegenerative diseases

2. Cyclin-Dependent Kinase 4/6 Inhibitors for Treatment of Hormone Receptor–Positive, ERBB2-Negative Breast Cancer

3. Down-regulation of cyclin-dependent kinase 5 attenuates p53-dependent apoptosis of hippocampal CA1 pyramidal neurons following transient cerebral ischemia

4. CDK5: key regulator of apoptosis and cell survival;Roufayel R;Biomedicine,2019

5. Physiological and Pathological Roles of Cdk5: Potential Directions for Therapeutic Targeting in Neurodegenerative Disease

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Industrializing yeast as a drug repurposing platform for inherited metabolic diseases;2024-08-26